This effect can be counteracted by miR-622, which targets HULC to suppress EMT-related signaling, providing new insights into pancreatic ductal adenocarcinoma pathogenesis and potential therapeutic targets (60). This evidence concerns the gene HULC and pancreatic ductal adenocarcinoma.